ID   97-1 [Human bladder carcinoma]
AC   CVCL_8616
SY   TCC 97-1
DR   cancercelllines; CVCL_8616
DR   Cosmic; 1046701
DR   Cosmic; 1285108
DR   Cosmic; 1927314
DR   Cosmic; 2050433
DR   Cosmic; 2057438
DR   Cosmic; 2444253
DR   Cosmic; 2685934
DR   GEO; GSM1567849
DR   GEO; GSM1574542
DR   Wikidata; Q54605808
RX   PubMed=9436977;
RX   PubMed=10919661;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25997541;
RX   PubMed=29732388;
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Arg692Ter (c.2074C>T); ClinVar=VCV000048885; Zygosity=Homozygous (PubMed=23401075).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 20
//
RX   PubMed=9436977; DOI=10.1101/gad.12.2.163;
RA   Yeager T.R., DeVries S., Jarrard D.F., Kao C., Nakada S.Y., Moon T.D.,
RA   Bruskewitz R., Stadler W.M., Meisner L.F., Gilchrist K.W.,
RA   Newton M.A., Waldman F.M., Reznikoff C.A.;
RT   "Overcoming cellular senescence in human cancer pathogenesis.";
RL   Genes Dev. 12:163-174(1998).
//
RX   PubMed=10919661;
RA   Sarkar S., Julicher K.P., Burger M.S., Della Valle V., Larsen C.-J.,
RA   Yeager T.R., Grossman T.B., Nickells R.W., Protzel C., Jarrard D.F.,
RA   Reznikoff C.A.;
RT   "Different combinations of genetic/epigenetic alterations inactivate
RT   the p53 and pRb pathways in invasive human bladder cancers.";
RL   Cancer Res. 60:3862-3871(2000).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//